From Big Pharma to little Tessera, Michael Severino rewrites his next chapter as CEO of Flagship biotech
Michael Severino, M.D., is leaving AbbVie and big pharma behind—but that’s not the end of the story. The leader is already entering his next chapter at Tessera Therapeutics, stepping into the world of biotech as CEO of the gene writing and rewriting company.